Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23569834 | 0.82 | CA2 (0.36) | CA2CA1CA12CA9 | |
| SCHEMBL5149907 | 0.76 | CA2 (0.52) | CA2CA1CA12CA9CA4 | |
| SCHEMBL1416183 | 0.76 | CES2 (0.38) | CA2 | |
| SCHEMBL6282064 | 0.76 | CES2 (0.43) | CA2 | |
| SCHEMBL2180225 | 0.76 | CES2 (0.38) | CA2 | |
| SCHEMBL28047295 | 0.76 | CA2 (0.59) | CA2 | |
| SCHEMBL4645608 | 0.74 | CA2 (0.50) | CA2CA1CA12CA9CA4 | |
| SCHEMBL5138444 | 0.74 | CES2 (0.41) | CA2 | |
| SCHEMBL2009694 | 0.74 | CA2 (0.58) | CA2CA1CA12CA9 | |
| SCHEMBL23531742 | 0.74 | CA2 (0.50) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | claimed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2023-04-13 | — | — | US | disclosed |
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2081889-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2005058299-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-0984961-B1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| US-6143751-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2000-11-07 | — | — | US | disclosed |
| CN-1258296-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRA PHARMA PROD (GB) | 2000-06-28 | — | — | CN | disclosed |
| EP-0984961-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998043971-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | CA2 2761/4885CA1 4200/4885CA12 4371/4885 |
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | CA2 1137/4885CA1 2532/4885CA12 1405/4885 |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | AARS1, ASNS, GARS1 | CA2 2761/4885CA1 4200/4885CA12 4371/4885 |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | CA2 4825/4885CA1 4867/4885CA12 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.